Literature DB >> 25637710

Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses.

Jennifer P Wang1, Robert W Finberg1, Gabriel L Hendricks1, Lourdes Velazquez2, Serena Pham1, Natasha Qaisar1, James C Delaney3, Karthik Viswanathan3, Leila Albers4, James C Comolli4, Zachary Shriver3, David M Knipe5, Evelyn A Kurt-Jones1, Deborah K Fygenson2, Jose M Trevejo4.   

Abstract

Heparan sulfate (HS) is a ubiquitous glycosaminoglycan that serves as a cellular attachment site for a number of significant human pathogens, including respiratory syncytial virus (RSV), human parainfluenza virus 3 (hPIV3), and herpes simplex virus (HSV). Decoy receptors can target pathogens by binding to the receptor pocket on viral attachment proteins, acting as 'molecular sinks' and preventing the pathogen from binding to susceptible host cells. Decoy receptors functionalized with HS could bind to pathogens and prevent infection, so we generated decoy liposomes displaying HS-octasaccharide (HS-octa). These decoy liposomes significantly inhibited RSV, hPIV3, and HSV infectivity in vitro to a greater degree than the original HS-octa building block. The degree of inhibition correlated with the density of HS-octa displayed on the liposome surface. Decoy liposomes with HS-octa inhibited infection of viruses to a greater extent than either full-length heparin or HS-octa alone. Decoy liposomes were effective when added prior to infection or following the initial infection of cells in vitro. By targeting the well-conserved receptor-binding sites of HS-binding viruses, decoy liposomes functionalized with HS-octa are a promising therapeutic antiviral agent and illustrate the utility of the liposome delivery platform.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Decoy; Heparin; Herpes simplex virus; Liposome; Parainfluenza virus; Respiratory syncytial virus

Mesh:

Substances:

Year:  2015        PMID: 25637710      PMCID: PMC4988063          DOI: 10.1016/j.antiviral.2015.01.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  36 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  How does cellular heparan sulfate function in viral pathogenicity?

Authors:  Wuyang Zhu; Jiangjiao Li; Guodong Liang
Journal:  Biomed Environ Sci       Date:  2011-02       Impact factor: 3.118

3.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate.

Authors:  Andres Chang; Cyril Masante; Ursula J Buchholz; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

5.  An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses.

Authors:  Chao-Tan Guo; Xue-Long Sun; Osamu Kanie; Kennedy Francis Shortridge; Takashi Suzuki; Daisei Miyamoto; Kazuya I-P Jwa Hidari; Chi-Huey Wong; Yasuo Suzuki
Journal:  Glycobiology       Date:  2002-03       Impact factor: 4.313

6.  The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus.

Authors:  Kicki Nyberg; Maria Ekblad; Tomas Bergström; Craig Freeman; Christopher R Parish; Vito Ferro; Edward Trybala
Journal:  Antiviral Res       Date:  2004-07       Impact factor: 5.970

7.  Molecular basis of glycosaminoglycan heparin binding to the chemokine CXCL1 dimer.

Authors:  Krishna Mohan Poluri; Prem Raj B Joseph; Kirti V Sawant; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2013-07-17       Impact factor: 5.157

8.  Role of heparan sulfate in human parainfluenza virus type 3 infection.

Authors:  Santanu Bose; Amiya K Banerjee
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

9.  The soluble form of two N-terminal domains of the poliovirus receptor is sufficient for blocking viral infection.

Authors:  A Zibert; H C Selinka; O Elroy-Stein; E Wimmer
Journal:  Virus Res       Date:  1992-09-01       Impact factor: 3.303

10.  Diversity in glycosaminoglycan binding amongst hMPV G protein lineages.

Authors:  Penelope Adamson; Sutthiwan Thammawat; Gamaliel Muchondo; Tania Sadlon; David Gordon
Journal:  Viruses       Date:  2012-12-14       Impact factor: 5.048

View more
  6 in total

Review 1.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?

Authors:  Valeria Cagno; Eirini D Tseligka; Samuel T Jones; Caroline Tapparel
Journal:  Viruses       Date:  2019-07-01       Impact factor: 5.048

Review 3.  Nanotechnology for virus treatment.

Authors:  Jiarong Zhou; Nishta Krishnan; Yao Jiang; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Today       Date:  2020-12-01       Impact factor: 20.722

Review 4.  Polymers Inspired by Heparin and Heparan Sulfate for Viral Targeting.

Authors:  Miriam Hoffmann; Nicole L Snyder; Laura Hartmann
Journal:  Macromolecules       Date:  2022-09-11       Impact factor: 6.057

5.  Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.

Authors:  Sameer Joshi; Atul A Chaudhari; Vida Dennis; Daniel J Kirby; Yvonne Perrie; Shree Ram Singh
Journal:  Bioengineering (Basel)       Date:  2018-05-09

Review 6.  Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic Viruses.

Authors:  Bimalendu Ray; Imran Ali; Subrata Jana; Shuvam Mukherjee; Saikat Pal; Sayani Ray; Martin Schütz; Manfred Marschall
Journal:  Viruses       Date:  2021-12-24       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.